Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The valuation ratios exhibit notable fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. A general trend of increasing valuation multiples is apparent, particularly in the later quarters, though with considerable variability. The period demonstrates a shift towards higher relative valuations across all measured metrics.
- Price to Earnings (P/E)
- The Price to Earnings ratio began at 21.64 and generally decreased through the first three quarters of 2022, reaching a low of 19.16. It then experienced a substantial increase, peaking at 63.84 in December 2022. This upward trajectory continued into 2023 and 2024, reaching 79.59 by December 2024, before a significant drop to 94.06 in December 2025. A peak of 92.57 was observed in June 2025, followed by a decline. The ratio demonstrates considerable volatility.
- Price to Operating Profit (P/OP)
- The Price to Operating Profit ratio showed relative stability between March 2022 and December 2022, fluctuating between 14.12 and 16.15. A marked increase began in 2023, accelerating through 2024 to reach 37.26 by December 2024. This trend partially reversed in 2025, decreasing to 26.37 by December 2025. The overall trend indicates increasing valuation relative to operating profit, though with a recent moderation.
- Price to Sales (P/S)
- The Price to Sales ratio remained relatively stable between 4.28 and 4.76 from March 2022 to September 2022. An upward trend commenced in late 2022, continuing through 2023 and 2024, peaking at 6.38 in September 2024. The ratio remained elevated in 2025, concluding the period at 6.50. This suggests a growing valuation relative to revenue generation.
- Price to Book Value (P/BV)
- The Price to Book Value ratio exhibited a consistent increase throughout the observed period. Starting at 16.59 in March 2022, it rose steadily to 20.62 by June 2023. The most dramatic increase occurred between September 2023 and March 2025, escalating from 20.61 to 229.63. The final two periods show missing values, indicating a potential data gap. This represents a substantial shift in valuation relative to net asset value.
In summary, the observed valuation ratios generally increased over the period, particularly the Price to Book Value ratio, which experienced exponential growth. The Price to Earnings and Price to Operating Profit ratios also demonstrated significant increases, albeit with more fluctuation. The Price to Sales ratio showed a more moderate, but consistent, upward trend. These changes suggest a shift in investor sentiment and potentially altered expectations regarding future growth and profitability.
AI Ask an analyst for more
Price to Earnings (P/E)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 1,768,169,012 | 1,767,384,632 | 1,766,558,253 | 1,766,403,027 | 1,765,354,859 | 1,767,140,323 | 1,766,343,745 | 1,765,867,781 | 1,766,473,359 | 1,765,537,421 | 1,765,046,680 | 1,764,289,680 | 1,769,399,971 | 1,768,480,508 | 1,768,096,495 | 1,767,110,083 | |||||
| Selected Financial Data (US$) | |||||||||||||||||||||
| Net earnings attributable to AbbVie Inc. (in millions) | 1,816) | 186) | 938) | 1,286) | (22) | 1,561) | 1,370) | 1,369) | 822) | 1,778) | 2,024) | 239) | 2,473) | 3,949) | 924) | 4,490) | |||||
| Earnings per share (EPS)2 | 2.39 | 1.35 | 2.13 | 2.37 | 2.42 | 2.90 | 3.02 | 3.39 | 2.75 | 3.69 | 4.92 | 4.30 | 6.69 | 7.58 | 7.15 | 7.06 | |||||
| Share price1, 3 | 224.81 | 215.89 | 197.19 | 184.60 | 192.87 | 200.47 | 187.51 | 163.79 | 175.75 | 141.20 | 150.33 | 148.03 | 151.31 | 145.28 | 138.92 | 152.83 | |||||
| Valuation Ratio | |||||||||||||||||||||
| P/E ratio4 | 94.06 | 159.78 | 92.57 | 77.73 | 79.59 | 69.16 | 62.04 | 48.26 | 63.84 | 38.27 | 30.55 | 34.43 | 22.62 | 19.16 | 19.44 | 21.64 | |||||
| Benchmarks | |||||||||||||||||||||
| P/E Ratio, Competitors5 | |||||||||||||||||||||
| Amgen Inc. | 25.81 | 24.59 | 23.15 | 25.49 | 38.24 | 40.68 | 53.65 | 44.38 | 23.14 | 18.09 | 16.31 | 16.18 | 19.56 | 21.00 | 20.03 | 22.23 | |||||
| Bristol-Myers Squibb Co. | 17.30 | 15.38 | 17.46 | 18.29 | — | — | — | — | 12.27 | 13.01 | 15.93 | 19.43 | 23.97 | 23.71 | 24.14 | 25.64 | |||||
| Danaher Corp. | 40.93 | 44.52 | 39.84 | 36.51 | 38.12 | 48.49 | 45.39 | 42.59 | 39.09 | 24.76 | 29.99 | 25.00 | 25.65 | 26.65 | 32.73 | 32.15 | |||||
| Eli Lilly & Co. | 47.45 | 43.36 | 43.95 | 67.76 | 77.63 | 96.05 | 109.42 | 120.94 | 135.24 | 110.43 | 76.21 | 65.16 | 50.08 | 55.53 | 51.05 | 45.29 | |||||
| Gilead Sciences Inc. | 21.54 | 18.18 | 21.68 | 20.62 | 296.57 | 925.87 | 89.29 | 166.76 | 16.17 | 17.10 | 17.88 | 17.75 | 22.68 | 29.30 | 18.66 | 17.25 | |||||
| Johnson & Johnson | 21.66 | 18.51 | 18.02 | 17.14 | 26.92 | 27.19 | 10.11 | 9.46 | 10.73 | 10.12 | 33.35 | 33.43 | 22.97 | 23.52 | 24.98 | 23.95 | |||||
| Merck & Co. Inc. | 16.79 | 11.00 | 12.30 | 11.98 | 13.49 | 20.98 | 20.73 | 140.05 | 893.99 | 56.85 | 86.53 | 22.92 | 19.21 | 16.41 | 13.36 | 15.70 | |||||
| Pfizer Inc. | 19.83 | 14.06 | 13.09 | 17.22 | 18.42 | 37.00 | — | — | 73.42 | 16.60 | 9.42 | 7.44 | 7.58 | 8.81 | 9.56 | 11.11 | |||||
| Regeneron Pharmaceuticals Inc. | 18.19 | 15.03 | 13.29 | 13.65 | 17.76 | 19.79 | 27.88 | 26.78 | 25.99 | 22.35 | 19.48 | 19.77 | 19.68 | 14.98 | 11.67 | 9.15 | |||||
| Thermo Fisher Scientific Inc. | 28.82 | 32.45 | 26.56 | 24.55 | 32.03 | 34.78 | 37.81 | 36.21 | 35.65 | 29.57 | 37.01 | 34.99 | 30.55 | 27.64 | 31.09 | 28.15 | |||||
| Vertex Pharmaceuticals Inc. | 31.58 | 29.11 | 26.43 | — | — | — | — | 26.34 | 30.42 | 28.09 | 27.49 | 27.34 | 23.02 | 24.62 | 23.12 | 26.50 | |||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2025 Calculation
EPS
= (Net earnings attributable to AbbVie Inc.Q4 2025
+ Net earnings attributable to AbbVie Inc.Q3 2025
+ Net earnings attributable to AbbVie Inc.Q2 2025
+ Net earnings attributable to AbbVie Inc.Q1 2025)
÷ No. shares of common stock outstanding
= (1,816,000,000 + 186,000,000 + 938,000,000 + 1,286,000,000)
÷ 1,768,169,012 = 2.39
3 Closing price as at the filing date of AbbVie Inc. Quarterly or Annual Report.
4 Q4 2025 Calculation
P/E ratio = Share price ÷ EPS
= 224.81 ÷ 2.39 = 94.06
5 Click competitor name to see calculations.
The price-to-earnings (P/E) ratio exhibited considerable fluctuation throughout the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicated a relatively stable P/E ratio, followed by a period of increasing volatility and, ultimately, a return towards more moderate levels.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The P/E ratio began at 21.64 and generally decreased through June 30, 2022, reaching 19.44. A slight recovery was observed through September 30, 2022, before increasing to 22.62 by the end of the year. This initial period suggests a moderate level of investor valuation, with some fluctuation but remaining within a relatively narrow range.
- Significant Increase (Mar 31, 2023 – Dec 31, 2023)
- A substantial increase in the P/E ratio commenced in the first quarter of 2023, rising from 34.43 to a peak of 63.84 by December 31, 2023. This surge coincided with a decrease in earnings per share (EPS), indicating that the share price was increasing at a faster rate than earnings. This period reflects a significant shift in investor sentiment, potentially driven by future growth expectations or market speculation.
- Moderation and Fluctuation (Mar 31, 2024 – Jun 30, 2025)
- Following the peak, the P/E ratio experienced a decline to 48.26 by March 31, 2024, followed by further increases to 69.16 and 79.59 in the subsequent quarters. The ratio then decreased to 77.73 and increased sharply to 92.57, before peaking at 159.78 in September 2025. Finally, the P/E ratio decreased to 94.06 by the end of the observed period. This phase demonstrates continued volatility, with the ratio remaining elevated compared to the initial period, but showing signs of stabilization towards the end of the timeframe.
- Relationship to Earnings Per Share
- The observed fluctuations in the P/E ratio are closely linked to changes in earnings per share. Periods of increasing P/E ratios often corresponded with decreasing EPS, and vice versa. This inverse relationship highlights the dynamic interplay between share price and earnings in determining investor valuation. The most dramatic increase in P/E occurred when EPS fell significantly in the latter half of 2023.
In summary, the P/E ratio demonstrated a clear progression from relative stability to significant volatility and a subsequent attempt at moderation. The substantial increases observed in 2023 and 2025 warrant further investigation to understand the underlying drivers of investor sentiment and earnings performance.
AI Ask an analyst for more
Price to Operating Profit (P/OP)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 1,768,169,012 | 1,767,384,632 | 1,766,558,253 | 1,766,403,027 | 1,765,354,859 | 1,767,140,323 | 1,766,343,745 | 1,765,867,781 | 1,766,473,359 | 1,765,537,421 | 1,765,046,680 | 1,764,289,680 | 1,769,399,971 | 1,768,480,508 | 1,768,096,495 | 1,767,110,083 | |||||
| Selected Financial Data (US$) | |||||||||||||||||||||
| Operating earnings (in millions) | 4,544) | 1,904) | 4,894) | 3,733) | (1,490) | 3,831) | 3,998) | 2,798) | 3,195) | 2,281) | 4,513) | 2,768) | 5,502) | 4,603) | 3,295) | 4,717) | |||||
| Operating profit per share2 | 8.53 | 5.12 | 6.21 | 5.70 | 5.18 | 7.82 | 6.95 | 7.24 | 7.22 | 8.53 | 9.85 | 9.16 | 10.24 | 10.00 | 9.84 | 10.49 | |||||
| Share price1, 3 | 224.81 | 215.89 | 197.19 | 184.60 | 192.87 | 200.47 | 187.51 | 163.79 | 175.75 | 141.20 | 150.33 | 148.03 | 151.31 | 145.28 | 138.92 | 152.83 | |||||
| Valuation Ratio | |||||||||||||||||||||
| P/OP ratio4 | 26.37 | 42.20 | 31.76 | 32.37 | 37.26 | 25.63 | 26.99 | 22.62 | 24.34 | 16.55 | 15.26 | 16.15 | 14.78 | 14.52 | 14.12 | 14.57 | |||||
| Benchmarks | |||||||||||||||||||||
| P/OP Ratio, Competitors5 | |||||||||||||||||||||
| Amgen Inc. | 21.92 | 19.86 | 18.71 | 20.31 | 21.55 | 27.68 | 27.12 | 23.97 | 19.69 | 15.45 | 13.71 | 14.25 | 13.40 | 14.89 | 14.08 | 15.88 | |||||
| Bristol-Myers Squibb Co. | 12.20 | 10.25 | 11.07 | 13.65 | — | — | — | — | 13.53 | 14.14 | 16.24 | 17.09 | 18.29 | 17.79 | 18.62 | 20.32 | |||||
| Danaher Corp. | 31.54 | 33.80 | 30.79 | 28.49 | 30.56 | 39.52 | 38.14 | 37.52 | 35.64 | 23.61 | 27.01 | 21.31 | 20.97 | 20.71 | 25.91 | 26.48 | |||||
| Eli Lilly & Co. | 37.24 | 34.60 | 35.19 | 53.43 | 63.73 | 79.30 | 88.66 | 99.34 | 109.75 | 93.27 | 69.42 | 59.60 | 43.88 | 46.48 | 39.20 | 36.49 | |||||
| Gilead Sciences Inc. | 18.29 | 14.06 | 17.00 | 14.96 | 85.65 | 143.05 | 36.80 | 51.26 | 12.05 | 12.16 | 11.57 | 11.21 | 14.21 | 16.27 | 11.02 | 10.78 | |||||
| Johnson & Johnson | 22.95 | 19.83 | 19.04 | 17.74 | 18.20 | 18.65 | 17.54 | 16.96 | 17.78 | 15.69 | 18.91 | 18.26 | 17.62 | 19.64 | 20.45 | 21.06 | |||||
| Merck & Co. Inc. | 14.44 | 9.67 | 10.57 | 10.37 | 11.60 | 18.67 | 18.41 | 75.94 | 138.56 | 33.75 | 44.67 | 18.53 | 15.55 | 13.85 | 11.72 | 14.29 | |||||
| Pfizer Inc. | 10.82 | 10.07 | 9.49 | 11.27 | 11.92 | 27.24 | — | — | 121.63 | 17.49 | 9.17 | 6.74 | 6.80 | 7.82 | 9.11 | 11.49 | |||||
| Regeneron Pharmaceuticals Inc. | 22.90 | 18.65 | 15.42 | 16.03 | 19.63 | 23.18 | 30.86 | 26.82 | 25.39 | 21.13 | 19.32 | 18.68 | 18.01 | 12.91 | 9.68 | 7.98 | |||||
| Thermo Fisher Scientific Inc. | 24.94 | 28.40 | 23.62 | 21.64 | 27.65 | 29.74 | 32.66 | 31.40 | 31.16 | 25.59 | 31.55 | 29.54 | 25.30 | 21.43 | 23.99 | 21.84 | |||||
| Vertex Pharmaceuticals Inc. | 29.92 | 26.79 | 24.50 | — | — | — | — | 25.25 | 28.74 | 25.14 | 23.33 | 22.03 | 17.75 | 19.41 | 18.11 | 22.13 | |||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2025 Calculation
Operating profit per share
= (Operating earningsQ4 2025
+ Operating earningsQ3 2025
+ Operating earningsQ2 2025
+ Operating earningsQ1 2025)
÷ No. shares of common stock outstanding
= (4,544,000,000 + 1,904,000,000 + 4,894,000,000 + 3,733,000,000)
÷ 1,768,169,012 = 8.53
3 Closing price as at the filing date of AbbVie Inc. Quarterly or Annual Report.
4 Q4 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 224.81 ÷ 8.53 = 26.37
5 Click competitor name to see calculations.
The Price to Operating Profit (P/OP) ratio for the analyzed period demonstrates considerable fluctuation. Initially, the ratio exhibited relative stability, followed by a period of significant volatility and a concluding trend towards moderation.
- Initial Stability (Mar 31, 2022 – Dec 31, 2022)
- From March 31, 2022, through December 31, 2022, the P/OP ratio remained within a narrow range, fluctuating between 14.12 and 14.78. This suggests a period of consistent valuation relative to operating profitability. Minor variations occurred, but the overall trend was largely flat.
- Increased Volatility (Mar 31, 2023 – Dec 31, 2023)
- Beginning March 31, 2023, the P/OP ratio began to exhibit increased volatility. A notable increase was observed, peaking at 26.99 on June 30, 2023, before declining to 24.34 by December 31, 2023. This period indicates a shift in investor sentiment or expectations regarding future operating performance. The ratio more than doubled from the beginning of this period to its peak.
- Peak and Subsequent Decline (Mar 31, 2024 – Sep 30, 2025)
- The ratio reached its highest point at 42.20 on September 30, 2025. This was preceded by a high of 37.26 on December 31, 2024. Following this peak, a decline was observed, with the ratio decreasing to 26.37 by December 31, 2025. This suggests a potential correction in valuation, possibly driven by changes in market conditions or company-specific factors. The decline, while substantial, did not return the ratio to the levels observed in the initial period.
- Relationship to Underlying Components
- The fluctuations in the P/OP ratio correlate with movements in both the share price and operating profit per share. Increases in the ratio are often associated with a rising share price, while decreases can be attributed to either a falling share price or a decline in operating profit per share, or a combination of both. The most significant increase in the P/OP ratio coincided with a substantial increase in share price and a relatively stable operating profit per share.
In summary, the P/OP ratio experienced a transition from initial stability to increased volatility, culminating in a peak followed by a partial decline. These changes suggest evolving investor perceptions of the company’s value relative to its operating profitability.
AI Ask an analyst for more
Price to Sales (P/S)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 1,768,169,012 | 1,767,384,632 | 1,766,558,253 | 1,766,403,027 | 1,765,354,859 | 1,767,140,323 | 1,766,343,745 | 1,765,867,781 | 1,766,473,359 | 1,765,537,421 | 1,765,046,680 | 1,764,289,680 | 1,769,399,971 | 1,768,480,508 | 1,768,096,495 | 1,767,110,083 | |||||
| Selected Financial Data (US$) | |||||||||||||||||||||
| Net revenues (in millions) | 16,618) | 15,776) | 15,423) | 13,343) | 15,102) | 14,460) | 14,462) | 12,310) | 14,301) | 13,927) | 13,865) | 12,225) | 15,121) | 14,812) | 14,583) | 13,538) | |||||
| Sales per share2 | 34.59 | 33.75 | 33.02 | 32.48 | 31.91 | 31.43 | 31.14 | 30.81 | 30.75 | 31.23 | 31.74 | 32.16 | 32.81 | 32.69 | 32.44 | 32.10 | |||||
| Share price1, 3 | 224.81 | 215.89 | 197.19 | 184.60 | 192.87 | 200.47 | 187.51 | 163.79 | 175.75 | 141.20 | 150.33 | 148.03 | 151.31 | 145.28 | 138.92 | 152.83 | |||||
| Valuation Ratio | |||||||||||||||||||||
| P/S ratio4 | 6.50 | 6.40 | 5.97 | 5.68 | 6.04 | 6.38 | 6.02 | 5.32 | 5.72 | 4.52 | 4.74 | 4.60 | 4.61 | 4.44 | 4.28 | 4.76 | |||||
| Benchmarks | |||||||||||||||||||||
| P/S Ratio, Competitors5 | |||||||||||||||||||||
| Amgen Inc. | 5.66 | 4.99 | 4.57 | 4.61 | 4.88 | 5.53 | 5.68 | 5.93 | 5.78 | 5.34 | 5.14 | 5.14 | 5.17 | 5.85 | 5.35 | 5.21 | |||||
| Bristol-Myers Squibb Co. | 2.53 | 1.93 | 1.85 | 2.08 | 2.36 | 2.38 | 2.20 | 1.99 | 2.19 | 2.40 | 2.81 | 3.10 | 3.29 | 3.39 | 3.39 | 3.41 | |||||
| Danaher Corp. | 6.02 | 6.43 | 5.66 | 5.77 | 6.23 | 7.95 | 8.10 | 7.90 | 7.76 | 5.63 | 6.77 | 5.76 | 5.79 | 5.66 | 6.59 | 6.68 | |||||
| Eli Lilly & Co. | 15.03 | 13.44 | 11.39 | 15.36 | 18.25 | 19.67 | 20.64 | 20.66 | 20.77 | 17.18 | 16.78 | 13.38 | 10.96 | 11.46 | 9.99 | 9.47 | |||||
| Gilead Sciences Inc. | 6.34 | 5.16 | 4.76 | 4.31 | 4.98 | 4.18 | 3.41 | 2.97 | 3.40 | 3.69 | 3.61 | 3.70 | 3.86 | 3.64 | 2.84 | 2.86 | |||||
| Johnson & Johnson | 6.16 | 5.04 | 4.51 | 4.19 | 4.26 | 4.55 | 4.44 | 4.25 | 4.43 | 4.01 | 4.84 | 4.60 | 4.34 | 4.69 | 4.80 | 5.00 | |||||
| Merck & Co. Inc. | 4.71 | 3.26 | 3.17 | 3.27 | 3.60 | 4.03 | 4.56 | 5.26 | 5.43 | 4.42 | 4.62 | 5.16 | 4.71 | 4.25 | 3.87 | 4.12 | |||||
| Pfizer Inc. | 2.46 | 2.20 | 2.20 | 2.17 | 2.32 | 2.60 | 3.00 | 2.86 | 2.61 | 2.51 | 2.58 | 2.32 | 2.37 | 2.63 | 2.77 | 3.00 | |||||
| Regeneron Pharmaceuticals Inc. | 5.71 | 4.83 | 4.17 | 4.36 | 5.52 | 6.65 | 8.93 | 7.89 | 7.84 | 6.81 | 6.61 | 6.69 | 7.01 | 5.87 | 4.66 | 4.40 | |||||
| Thermo Fisher Scientific Inc. | 4.34 | 4.87 | 4.05 | 3.73 | 4.73 | 5.04 | 5.55 | 5.14 | 4.99 | 4.05 | 4.87 | 4.81 | 4.73 | 4.40 | 5.40 | 5.20 | |||||
| Vertex Pharmaceuticals Inc. | 10.40 | 9.13 | 8.42 | 10.41 | 10.78 | 12.12 | 12.35 | 10.39 | 11.16 | 10.10 | 9.73 | 9.68 | 8.56 | 9.26 | 8.85 | 8.17 | |||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2025 Calculation
Sales per share
= (Net revenuesQ4 2025
+ Net revenuesQ3 2025
+ Net revenuesQ2 2025
+ Net revenuesQ1 2025)
÷ No. shares of common stock outstanding
= (16,618,000,000 + 15,776,000,000 + 15,423,000,000 + 13,343,000,000)
÷ 1,768,169,012 = 34.59
3 Closing price as at the filing date of AbbVie Inc. Quarterly or Annual Report.
4 Q4 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= 224.81 ÷ 34.59 = 6.50
5 Click competitor name to see calculations.
The price-to-sales (P/S) ratio for the analyzed period demonstrates considerable fluctuation. Initially, the ratio exhibited a slight decline from 4.76 to 4.28, followed by a modest recovery to 4.61. A significant increase then occurred, peaking at 5.72 before experiencing a pullback to 5.32. Subsequently, the ratio continued to climb, reaching 6.38 and then 6.04, before decreasing to 5.68. The final period shows an upward trend, culminating in a ratio of 6.50.
- Initial Phase (Mar 31, 2022 – Dec 31, 2022)
- The P/S ratio remained relatively stable, fluctuating within a narrow range of 4.28 to 4.76. This suggests a consistent valuation relative to sales during this timeframe. The initial decrease followed by a slight recovery could indicate short-term market sentiment shifts.
- Ascending Trend (Mar 31, 2023 – Jun 30, 2024)
- A clear ascending trend is observed, with the P/S ratio increasing from 4.60 to 6.02. This increase suggests investors were willing to pay a higher premium for each dollar of sales, potentially driven by positive expectations regarding future growth or profitability. The peak at 6.02 represents the highest valuation within the analyzed period.
- Recent Performance (Sep 30, 2024 – Dec 31, 2025)
- Following the peak, the P/S ratio experienced a slight decline to 6.04 before resuming its upward trajectory. The ratio concluded the period at 6.50, indicating continued investor confidence, albeit with some volatility. The final increase suggests a strengthening valuation relative to sales.
Throughout the period, the sales per share exhibited a gradual increase, moving from 32.10 to 34.59. This positive trend in sales per share likely contributed to the overall increase in the P/S ratio, particularly in the latter half of the analyzed timeframe. The correlation between increasing sales per share and the P/S ratio suggests that market valuation is responsive to revenue generation.
The most significant change observed is the substantial increase in the P/S ratio between March 2023 and June 2024. This period warrants further investigation to determine the underlying factors driving the increased valuation. The final period’s increase also suggests a positive market outlook.
AI Ask an analyst for more
Price to Book Value (P/BV)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 1,768,169,012 | 1,767,384,632 | 1,766,558,253 | 1,766,403,027 | 1,765,354,859 | 1,767,140,323 | 1,766,343,745 | 1,765,867,781 | 1,766,473,359 | 1,765,537,421 | 1,765,046,680 | 1,764,289,680 | 1,769,399,971 | 1,768,480,508 | 1,768,096,495 | 1,767,110,083 | |||||
| Selected Financial Data (US$) | |||||||||||||||||||||
| Stockholders’ equity (deficit) (in millions) | (3,270) | (2,642) | (183) | 1,420) | 3,325) | 6,032) | 6,778) | 8,007) | 10,360) | 12,094) | 12,866) | 13,274) | 17,254) | 15,994) | 14,653) | 16,283) | |||||
| Book value per share (BVPS)2 | -1.85 | -1.49 | -0.10 | 0.80 | 1.88 | 3.41 | 3.84 | 4.53 | 5.86 | 6.85 | 7.29 | 7.52 | 9.75 | 9.04 | 8.29 | 9.21 | |||||
| Share price1, 3 | 224.81 | 215.89 | 197.19 | 184.60 | 192.87 | 200.47 | 187.51 | 163.79 | 175.75 | 141.20 | 150.33 | 148.03 | 151.31 | 145.28 | 138.92 | 152.83 | |||||
| Valuation Ratio | |||||||||||||||||||||
| P/BV ratio4 | — | — | — | 229.63 | 102.40 | 58.73 | 48.87 | 36.12 | 29.97 | 20.61 | 20.62 | 19.68 | 15.52 | 16.06 | 16.76 | 16.59 | |||||
| Benchmarks | |||||||||||||||||||||
| P/BV Ratio, Competitors5 | |||||||||||||||||||||
| Amgen Inc. | 22.99 | 17.91 | 20.63 | 24.36 | 26.61 | 22.86 | 28.34 | 33.25 | 24.94 | 17.87 | 19.19 | 23.95 | 35.01 | 39.30 | 54.46 | 138.87 | |||||
| Bristol-Myers Squibb Co. | 6.61 | 5.01 | 5.06 | 5.70 | 6.98 | 6.60 | 6.01 | 5.49 | 3.35 | 3.72 | 3.97 | 4.46 | 4.88 | 4.85 | 4.90 | 5.07 | |||||
| Danaher Corp. | 2.82 | 3.05 | 2.60 | 2.70 | 3.00 | 3.68 | 3.82 | 3.51 | 3.47 | 2.78 | 3.65 | 3.33 | 3.64 | 3.77 | 4.36 | 4.36 | |||||
| Eli Lilly & Co. | 36.91 | 33.55 | 33.19 | 47.74 | 57.93 | 56.45 | 59.24 | 57.94 | 65.80 | 49.10 | 44.75 | 33.11 | 29.36 | 33.27 | 34.00 | 29.75 | |||||
| Gilead Sciences Inc. | 8.07 | 6.85 | 6.96 | 6.42 | 7.36 | 6.36 | 5.15 | 4.61 | 4.01 | 4.50 | 4.63 | 4.72 | 4.90 | 4.63 | 3.82 | 3.91 | |||||
| Johnson & Johnson | 7.12 | 5.86 | 5.20 | 4.79 | 5.30 | 5.69 | 5.37 | 5.20 | 5.48 | 4.92 | 5.79 | 6.00 | 5.37 | 6.04 | 6.01 | 6.36 | |||||
| Merck & Co. Inc. | 5.82 | 4.04 | 4.12 | 4.32 | 4.99 | 5.73 | 6.53 | 8.00 | 8.68 | 6.35 | 6.96 | 6.38 | 6.07 | 5.63 | 5.12 | 5.44 | |||||
| Pfizer Inc. | 1.78 | 1.49 | 1.59 | 1.50 | 1.68 | 1.70 | 1.92 | 1.74 | 1.75 | 1.80 | 2.04 | 2.14 | 2.48 | 2.83 | 3.21 | 3.37 | |||||
| Regeneron Pharmaceuticals Inc. | 2.62 | 2.22 | 1.98 | 2.09 | 2.67 | 3.14 | 4.27 | 3.83 | 3.96 | 3.58 | 3.49 | 3.52 | 3.77 | 3.75 | 3.21 | 3.65 | |||||
| Thermo Fisher Scientific Inc. | 3.62 | 4.18 | 3.46 | 3.24 | 4.09 | 4.36 | 4.96 | 4.80 | 4.57 | 3.88 | 4.84 | 4.99 | 4.83 | 4.46 | 5.47 | 5.23 | |||||
| Vertex Pharmaceuticals Inc. | 6.69 | 6.18 | 5.60 | 7.01 | 7.24 | 8.24 | 8.64 | 5.71 | 6.26 | 5.90 | 5.98 | 6.18 | 5.50 | 6.18 | 6.19 | 5.95 | |||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2025 Calculation
BVPS = Stockholders’ equity (deficit) ÷ No. shares of common stock outstanding
= -3,270,000,000 ÷ 1,768,169,012 = -1.85
3 Closing price as at the filing date of AbbVie Inc. Quarterly or Annual Report.
4 Q4 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= 224.81 ÷ -1.85 = —
5 Click competitor name to see calculations.
The price to book value (P/BV) ratio exhibits a notable upward trend over the observed period, punctuated by periods of relative stability. Initially, the ratio fluctuated within a relatively narrow range before experiencing significant increases in later quarters.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The P/BV ratio began at 16.59 and demonstrated modest variability, ranging from a low of 15.52 to a high of 16.76. This suggests a generally consistent market valuation relative to book value during this timeframe.
- Transition and Acceleration (Mar 31, 2023 – Jun 30, 2023)
- A noticeable increase commenced in the first half of 2023, with the P/BV ratio rising from 19.68 to 20.62. While still within a manageable range, this signals a shift in market perception.
- Significant Increase (Sep 30, 2023 – Dec 31, 2024)
- The period from September 2023 through December 2024 witnessed a dramatic escalation in the P/BV ratio. It increased from 20.61 to 102.40, indicating a substantial premium placed on the company’s stock price relative to its book value. This acceleration suggests a significant change in investor sentiment, potentially driven by factors not reflected in book value alone.
- Recent Period (Mar 31, 2025 – Dec 31, 2025)
- The P/BV ratio continued to climb, reaching 229.63 by March 2025. Subsequent periods show further increases, culminating in a ratio of 224.81 by December 2025. This continued upward trajectory suggests a sustained and potentially escalating market valuation.
Concurrently, the book value per share (BVPS) experienced a declining trend, particularly pronounced in the latter half of the observation period. Starting at 9.21, BVPS decreased to -1.85 by December 2025. This decline in BVPS, coupled with the increasing share price, is a primary driver of the observed increase in the P/BV ratio.
- Book Value Per Share Trend
- The consistent decrease in BVPS, transitioning from positive values to negative values, indicates a reduction in the net asset value attributable to each share. This trend contrasts sharply with the increasing share price and contributes significantly to the escalating P/BV ratio.
The substantial increase in the P/BV ratio, alongside the declining BVPS, suggests that the market is placing a significantly higher value on the company’s future earnings potential, intangible assets, or other factors not fully captured in its book value. The ratio’s progression indicates a growing disconnect between market valuation and the company’s net asset value.
AI Ask an analyst for more